Eli Lilly’s diabetes drug Mounjaro was rebranded as Zepbound in the U.S. following FDA approval for weight loss. The medication is the same, with the same strength, and has already been recommended for weight loss in Europe. The company did not explain the reasoning behind the new name, but experts believe it reflects the marketing differences between the U.S. and Europe. The naming process reveals the effort to create a distinctive brand identity for the drug. The new branding strategy has sparked opinions among consumers, with some liking it and others comparing it to a bus line. Meanwhile, the drug’s competitors have different strengths for diabetes and weight loss.